<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of compound sickle cell syndromes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of compound sickle cell syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of compound sickle cell syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliott P Vichinsky, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R DeBaun, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Compound sickle cell syndromes include any hemoglobinopathy in which the sickle mutation is inherited in combination with another globin gene mutation (affecting alpha globin, beta globin, or gamma globin). These syndromes may have different clinical severity compared with homozygous sickle mutation (Hb SS).</p><p>This topic presents an overview of the compound sickle cell syndromes and their clinical features.</p><p>Related subjects including the diagnosis of sickle cell syndromes, clinical manifestations, and management, as well as sickle cell trait (generally a benign carrier state) are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prenatal testing – (See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Diagnosis – (See  <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Further details about laboratory methods – (See  <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Clinical manifestations – (See  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Management – (See  <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a> and  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell trait</strong> – (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait"</a>.)</p><p></p><p></p><p class="headingAnchor" id="H1844665773"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H1107626239"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>Vaso-occlusive phenomena and hemolytic anemia are the clinical hallmarks of sickle cell disease (SCD). Vaso-occlusion results in recurrent painful episodes and a variety of serious organ system complications that can lead to life-long disabilities and even death.</p><p>Hemoglobin S (Hb S) results from the substitution of a valine for glutamic acid as the seventh amino acid of the beta-globin chain, which produces a hemoglobin tetramer (alpha2/betaS2) that is poorly soluble when deoxygenated [<a href="#rid1">1</a>]. The polymerization of deoxy Hb S is essential to vaso-occlusive phenomena [<a href="#rid1">1</a>]. The polymer assumes the form of an elongated rope-like fiber which usually aligns with other fibers, resulting in distortion of the affected red blood cell into the classic crescent or sickle shape and a marked decrease in red cell deformability. (See  <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Effects on the RBC'</a>.)</p><p>However, polymerization alone does not account for the pathophysiology of SCD. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play an important role [<a href="#rid1">1,2</a>].</p><p>The three most common genotypes accounting for SCD are homozygous Hb SS and two compound sickle cell syndromes, sickle–beta thalassemia and hemoglobin SC (Hb SC) disease. </p><p class="headingAnchor" id="H204532291"><span class="h2">Comparison with sickle cell disease</span><span class="headingEndMark"> — </span>SCD clinical manifestations are similar in compound heterozygous individuals as in homozygous Hb SS, but they vary in severity (from mild, to as severe as in Hb SS). The clinical heterogeneity in different SCD genotypes is accounted for by the hemoglobin variant that accompanies Hb S, such as Hb D, Hb C, or Hb E, or a variant causing beta thalassemia. While compound heterozygous genotypes generally have a less severe clinical course than Hb SS, there are compound heterozygotes for SCD who have clinical manifestations similar to Hb SS; these include Hb S-beta<sup>0</sup> thalassemia, Hb SD, and Hb S-O Arab. Any individual with a compound heterozygous SCD genotype may have a more severe clinical course than an individual with Hb SS. (See <a class="local">'Sickle-beta thalassemia'</a> below and <a class="local">'Sickle-Hb D disease'</a> below and <a class="local">'Sickle-Hb O Arab disease'</a> below.)</p><p>The implications include extending screening, such as transcranial Doppler screening to identify candidates for stroke prevention, in children with most of the compound sickle cell syndromes, with the exception of Hb SC disease. The American Society of Hematology (ASH) 2020 guidelines for sickle cell disease recommend that transcranial Doppler (TCD) screening should be performed in children who have compound heterozygous SCD other than Hb SC, including <em>Hb S-Lepore disease, Hb SE disease, Hb S-O Arab disease, or Hb SD disease phenotypes,</em> and who have evidence of hemolysis in the same range as those with Hb SS [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease"</a>.)</p><p>In addition, specific complications, such as retinopathy in Hb SC, are more frequent in otherwise mild compound sickle cell syndromes. Viral infections, including Dengue and COVID-19, may be more severe in compound heterozygotes, possibly because of their association with fat embolism syndrome [<a href="#rid4">4-9</a>]. </p><p>People with Hb SC disease and Hb S beta+ thalassemia tend to have an increased incidence of elevated body mass index (BMI) relative to individuals with SCD. This is likely a factor in pain severity and overall morbidity [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H1089729873"><span class="h2">Unusual and confusing laboratory presentations for non-sickle cell disorders and suggestive of sickle cell trait</span></p><p class="bulletIndent1"><span class="glyph">●</span>Occasionally, laboratory testing demonstrates a hemoglobin pattern with Hb S &lt;50 percent, Hb A2 &gt;3.5 percent, and Hb A present. These cases represent sickle cell trait (Hb AS, in which one sickle beta globin gene and one normal beta globin gene are present). The SCD phenotype (based on CBC and hemoglobin analysis) as opposed to the SCD genotype (based on beta globin gene sequence) may be confused with sickle cell-beta thalassemia because of an elevated Hb A2. However, Hb A2 levels are often falsely elevated in the presence of Hb S. Any time the proportion of Hb S is less than 50 percent, the individual has a sickle trait, regardless of the Hb A2 level. Sickle cell trait is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait"</a>.)</p><p></p><p class="bulletIndent1">In a review of newborn screening program results for hemoglobin FSA using protein methods, 30 newborns initially identified as having sickle beta<sup>+</sup> thalassemia had the diagnosis corrected to sickle cell trait [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sickle-cell-delta-beta<sup>+</sup> thalassemia results from heterozygosity for the sickle mutation and heterozygosity for a delta-beta (δβ) fusion gene. This combination is seen in people of Senegalese descent. This is a very mild form of SCD, with patients often asymptomatic. Laboratory testing shows microcytosis, hemoglobin &gt;10 g/dL, elevated Hb S &gt;50 percent, and Hb A and Hb F &gt;12 percent [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">In contrast to sickle-cell-delta beta<sup>0</sup> thalassemia (see <a class="local">'Sickle-delta beta(0) thalassemia'</a> below), sickle-cell-delta–beta<sup>+</sup> thalassemia produces some normal Hb A. Overall, the population of individuals with this genotype is likely to have milder disease, but any individual may have more severe disease.</p><p></p><p class="headingAnchor" id="H1375116479"><span class="h1">SPECIFIC COMPOUND SICKLE CELL SYNDROMES</span></p><p class="headingAnchor" id="H2"><span class="h2">Hb SC disease</span></p><p class="headingAnchor" id="H3"><span class="h3">Pathophysiology</span><span class="headingEndMark"> — </span>The Hb C variant in the beta globin locus (<em>HBB </em>p.Glu7Lys) is approximately one-fourth as common among African Americans as the sickle cell variant [<a href="#rid13">13</a>]. Although oxygenated Hb C forms crystals, Hb C does not participate in polymerization with deoxy Hb S [<a href="#rid14">14,15</a>]. Worldwide, there are at least 55,000 births annually, with the highest frequency in West Africa. (See  <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb C'</a>.)</p><p>The presence of Hb C within the cell leads to enhanced and sustained potassium and chloride cotransport. The loss of K<sup>+</sup> produces red cell dehydration and an increase in the intraerythrocytic concentration of Hb S to levels that may support polymerization, sickling, and clinical symptoms [<a href="#rid14">14,16</a>]. In vitro studies have found that, at the same total Hb concentration, a 50:50 Hb S and Hb C mixture undergoes polymerization 15 times more rapidly than a 40:60 Hb S and Hb A mixture; this difference is presumably due to the higher Hb S concentration [<a href="#rid14">14</a>]. The net effect is that compound heterozygosity for Hb S and C results in a disease (Hb SC) that is less severe than sickle cell disease (SCD) but more severe than sickle cell trait [<a href="#rid17">17,18</a>]. </p><p class="headingAnchor" id="H1619955730"><span class="h3">Laboratory</span><span class="headingEndMark"> — </span>Hemoglobin analysis shows approximately equal amounts of Hb S and Hb C (or slightly more Hb S than Hb C), with no Hb A present. If cellulose acetate electrophoresis is used, Hb C may migrate with Hb S E, O-Arab, and C-Harlem. Thus, two independent hemoglobin electrophoresis techniques are necessary in order to distinguish Hb SC from Hb SC Harlem and other compound heterozygotes. The predominant red cell abnormality on the peripheral smear is an abundance of target cells. Sickled cells are relatively uncommon; rare sickled cells may be canoe-shaped  (<a class="graphic graphic_picture graphicRef71393" href="/z/d/graphic/71393.html" rel="external">picture 1</a>). Folded (pita bread, clam-shell) cells, irreversibly sickled cells, "billiard ball" cells, and crystal-containing cells also may be seen  (<a class="graphic graphic_picture graphicRef71393" href="/z/d/graphic/71393.html" rel="external">picture 1</a>) [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a>.)</p><p>Anemia and reticulocytosis are typically mild, with the majority of patients having a milder degree of anemia (hematocrit &gt;28 percent) than is usually seen in SCD. Markers of hemolysis are lower than in Hb SS [<a href="#rid20">20</a>]. This difference is due to the longer survival of Hb SC compared with Hb SS red cells in the circulation (27 versus 17 days) [<a href="#rid21">21,22</a>]. Similarly, markers of inflammation are lower [<a href="#rid20">20</a>]. However, the lipid profiles are higher. </p><p class="headingAnchor" id="H4"><span class="h3">Clinical course</span><span class="headingEndMark"> — </span>The clinical findings include relatively normal weight, growth, and physical development; splenomegaly is variable. Individuals with Hb SC disease are at risk for the same life-threatening complications as Hb SS but at a decreased frequency [<a href="#rid23">23</a>]. The effects of Hb F and alpha thalassemia on the severity of Hb SC disease are limited [<a href="#rid24">24</a>].</p><p>A small subset of individuals with Hb SC have a clinical phenotype similar to Hb SS. Overall, the clinical severity of Hb SC is milder, as indicated from the Cooperative Study of Sickle Cell Disease, which compared Hb SC disease with Hb SS. Data from Ghana reported that at least 10 percent of young adults with Hb SC disease had a severe clinical phenotype [<a href="#rid24">24</a>].</p><p> The following have been reported in individuals with Hb SC disease:</p><p class="bulletIndent1"><span class="glyph">●</span>A 50 percent lower rate of acute painful episodes (0.4 versus 0.8 per year) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lower risk of silent cerebral infarcts (3 versus 17 percent) [<a href="#rid26">26</a>] and of having a stroke (2 versus 11 percent incidence of a first stroke by age 20)  (<a class="graphic graphic_figure graphicRef61397" href="/z/d/graphic/61397.html" rel="external">figure 1</a>) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lower rate of focal segmental glomerulosclerosis (2.4 versus 4.2 percent in one study) with a later onset of progressive kidney failure (50 versus 23 years old at diagnosis) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lower incidence of fatal bacterial infection in young children [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A very low rate of leg ulcers [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Later development of osteonecrosis [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lesser delay in growth and sexual development [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A two-decade increase in life expectancy (64 versus 45 years) [<a href="#rid34">34</a>]. At two large academic SCD centers, there was no difference in the median survival of individuals with Hb SC compared to individuals with Hb SS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort study, the incidences of severe acute vaso-occlusive pain requiring hospitalization and pain events were no different in pregnant women with Hb SS and Hb SC during the third trimester and early postpartum period, the interval with the highest SCD related morbidity [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher incidence of peripheral retinopathy, thought to be related to the higher hematocrit in this disorder [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk for systemic and cerebral fat embolism. The overall incidence is unclear and may be higher than thought [<a href="#rid38">38</a>].</p><p></p><p>Cohort studies in individuals with Hb SC disease support the observations of the cooperative study above and highlight specific problems and treatments [<a href="#rid39">39-44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A clinical diagnosis is often delayed until a serious event during young adulthood because of the mild anemia and relatively benign clinical course in early pediatrics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rates of maternal-fetal morbidity, retinopathy, avascular necrosis of the hip, and chronic kidney disease are increased. While microalbuminuria is lower in Hb SC disease than Hb SS, it still occurs in over 23 percent of adults [<a href="#rid40">40</a>]. In addition, thrombosis, silent cerebral infarction, sensorineural hearing loss, and pulmonary hypertension may be higher than previously suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> therapy is beneficial in decreasing vaso-occlusive events and appears safe. Patients may develop reversible cytopenias and are at risk for hyperviscosity syndrome secondary to an increased hemoglobin, which requires therapeutic phlebotomy [<a href="#rid45">45</a>]. This combination is increasingly being used [<a href="#rid46">46</a>]. Pilot data using therapeutic phlebotomy alone suggest this may also lower the rate of vaso-occlusive events [<a href="#rid47">47,48</a>].</p><p></p><p>Functional asplenia occurs in many patients with Hb SC disease (45 percent in individuals over age 25 in one study) [<a href="#rid49">49</a>]. However, it does not occur prior to age four, and routine administration of prophylactic penicillin may not be necessary in infants and young children. (See  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p>The persistent splenic function means that splenic infarction and splenic sequestration crisis, which primarily occur in young children with SCD, can occur at all ages in Hb SC disease [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H2261634184"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment depends on clinical severity, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p>Studies from Ghana have documented that the subgroup of Hb SC patients with severe disease who met criteria for <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> were rarely treated [<a href="#rid24">24</a>]. Prospective studies of Hb SC disease treatment are needed. (See  <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Sickle-beta thalassemia</span><span class="headingEndMark"> — </span>Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one or more globin chains. Beta thalassemia is due to impaired production of beta globin chains, which leads to a relative excess of alpha globin chains. These excess alpha globin chains are unstable, incapable of forming soluble tetramers on their own, and precipitate within the cell, leading to a variety of clinical manifestations. (See  <a class="medical medical_review" href="/z/d/html/7090.html" rel="external">"Pathophysiology of thalassemia"</a>.)</p><p class="headingAnchor" id="H3290041"><span class="h3">Incidence and classification</span><span class="headingEndMark"> — </span>The gene frequency of beta thalassemia among African Americans is 0.004, one-tenth that of the sickle cell gene [<a href="#rid13">13</a>]. As a result, the prevalence of compound heterozygous sickle cell-beta thalassemia is one-tenth that of sickle cell anemia (Hb SS) in this population. In addition to the African American population, people of Hispanic descent are at risk for sickle-beta thalassemia. In California, 12.5 percent of newborns with sickle-beta thalassemia have Hispanic origin [<a href="#rid51">51</a>].</p><p>Sickle cell-beta thalassemia is divided into sickle cell-beta<sup>0</sup> thalassemia and sickle cell-beta<sup>+</sup> thalassemia, based upon the complete absence beta globin or the presence of reduced amounts of beta globin, respectively, which in turn determines the level of Hb A [<a href="#rid52">52,53</a>]. Most beta thalassemia mutations among African Americans result in beta<sup>+</sup> thalassemia. The percentage of Hb A produced in individuals with beta<sup>+</sup> thalassemia varies from 5 to 30 percent, depending upon the molecular defect of the mutation [<a href="#rid54">54-56</a>]. As an example, those with a beta thalassemia mutation of -29(A--&gt;G) have a high Hb A level and a mild clinical course.</p><p>Eighty percent of African American beta thalassemia pathogenic variants are due to promoter region mutations that result in a mild phenotype in which Hb A accounts for 18 to 25 percent of total hemoglobin [<a href="#rid54">54,55</a>]. The genotype for sickle-beta thalassemia varies in different regions in the world. Compound heterozygous sickle cell-beta<sup>0</sup> thalassemia, which results in the production of no normal beta chains and therefore no Hb A, occurs infrequently in the African American population, but more commonly in the Greek, Middle Eastern, and Mediterranean regions. The Brazilian REDS 3 NIH study analyzed 167 sickle-beta thalassemia patients and found that beta<sup>+</sup> and beta<sup>0</sup> mutations occurred in approximately equal proportions in people with sickle cell beta thalassemia [<a href="#rid57">57</a>]. However, half the sickle beta<sup>+</sup> variants were severe and clinically similar to sickle cell beta<sup>0</sup> thalassemia. Some of the variants in this group included IVS-I-110 (G&gt;A), IVS-I-5 (G&gt;C), and IVS-I-5 (G&gt;A). </p><p class="headingAnchor" id="H3021645631"><span class="h3">Diagnosis and misdiagnosis of Hb S-beta(0)</span><span class="headingEndMark"> — </span>The clinical and laboratory phenotype of Hb S-beta<sup>0</sup> thalassemia is similar to that in Hb SS. Nearly all the hemoglobin consists of Hb S, and there is no Hb A present. Microcytosis is a useful indicator of Hb S-beta<sup>0</sup> thalassemia. However, alpha thalassemia trait is a common finding and may cause microcytosis without a beta thalassemia mutation.</p><p>Distinguishing Hb SS from Hb S-beta<sup>0</sup> thalassemia is challenging, even for hematologists. In a study involving 809 children with a clinical diagnosis of Hb SS or Hb S-beta<sup>0</sup> thalassemia based on HLPLC or IEF and laboratory values, phenotypic misclassification occurred in 39 of 53 (74 percent) of those with Hb S-beta<sup>0</sup> thalassemia (they actually had a Hb SS genotype) and 6 of 698 (0.9 percent) of those with Hb SS (they actually had a Hb S-beta<sup>0</sup> genotype) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H3290054"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>The hematologic and clinical severity of sickle cell-beta thalassemia is an inverse function of the quantity of Hb A [<a href="#rid56">56,59</a>].</p><p>Patients with sickle cell-beta<sup>0</sup> thalassemia (no Hb A production) have a clinical course as severe as homozygous sickle cell disease (SCD; ie, Hb SS, sickle cell anemia) [<a href="#rid59">59</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The Cooperative Study of Sickle Cell Disease (over 3000 patients) found that the incidence and severity of painful events and acute chest syndrome were similar between individuals with Hb SS and hemoglobin S-beta<sup>0</sup> disease [<a href="#rid25">25,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review of 84 patients suggested that pulmonary hypertension is also comparable between sickle beta<sup>0</sup> thalassemia and Hb SS [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with Hb S-beta<sup>0</sup> thalassemia were found in some studies to have a high rate of ischemic brain injury [<a href="#rid27">27,62</a>]. However, in the absence of genotyping of the beta globin gene, these patients may have been misclassified and may actually have had Hb SS [<a href="#rid58">58</a>]. In neurologically asymptomatic individuals with Hb S-beta<sup>0</sup> thalassemia, transcranial Doppler and MRI abnormalities are found [<a href="#rid63">63</a>]. In the SIT trial, children with Hb S-beta<sup>0</sup> thalassemia based on genotyping had significantly lower TCD velocities than children with Hb SS, with the same prevalence of silent cerebral infarcts [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with Hb S-beta<sup>0</sup> thalassemia typically develop functional asplenia in early infancy, have an increased rate of sepsis, and have an associated increased risk of pneumococcal sepsis [<a href="#rid65">65</a>]. Depending on the percentage of hemoglobin A, individuals with Hb S-beta<sup>+</sup> thalassemia do not undergo the rapid splenic infarction seen in Hb SS. Individuals with Hb S-beta<sup>+</sup> thalassemia may continue to have splenic enlargement, often into adulthood, and they remain at risk for acute splenic sequestration episodes and hypersplenism.</p><p></p><p>Higher Hb A levels are generally associated with less severe clinical manifestations (individuals with Hb S-beta<sup>+</sup> thalassemia generally have a more benign clinical course than those with Hb S-beta<sup>0</sup> thalassemia or Hb SS). Acute painful events do occur, but are less than half those seen in Hb SS [<a href="#rid25">25</a>].</p><p>Despite the milder clinical course of individuals with Hb S-beta<sup>+</sup> thalassemia, an individual with Hb S-beta<sup>+</sup> thalassemia may have life-threatening episodes of acute chest syndrome, acute chest syndrome following surgery, complications of acute vaso-occlusive pain, or pregnancy related vaso-occlusive complications.</p><p>The lesser severity of Hb S-beta<sup>+</sup> thalassemia was illustrated in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>One study compared clinical findings in 27 patients with sickle cell-beta<sup>+</sup> thalassemia and 28 patients with Hb S-beta<sup>0</sup> thalassemia [<a href="#rid66">66</a>]. Compared with sickle cell-beta<sup>0</sup> thalassemia, those with Hb S-beta<sup>+</sup> thalassemia had the following findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Threefold higher incidence of incidental diagnosis (26 versus 9 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Later mean age of presentation (8.2 versus 3.2 years)</p><p class="bulletIndent2"><span class="glyph">•</span>Less frequent leg ulcers (8 versus 23 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Less frequent episodes of acute chest syndrome (14 versus 24 percent); this approximately 50 percent reduction in painful episodes has been noted in other reports [<a href="#rid25">25</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Less frequent priapism (0 versus 4 patients)</p><p class="bulletIndent2"><span class="glyph">•</span>Less frequent aplastic crises (0 versus 2 patients)</p><p></p><p class="bulletIndent1">Splenomegaly occurred in approximately one-third of both groups. There was a higher incidence of proliferative retinopathy in individuals with sickle cell-beta<sup>+</sup> thalassemia (18 versus 10 percent), consistent with an association of higher hematocrits (and blood viscosity) with ocular complications. Both Hb S-beta<sup>+</sup> thalassemia and Hb S-beta<sup>0</sup> thalassemia have a decreased incidence of stroke compared with Hb SS  (<a class="graphic graphic_figure graphicRef61397" href="/z/d/graphic/61397.html" rel="external">figure 1</a>) [<a href="#rid27">27</a>]. Some individuals with no history of clinical stroke have demonstrated silent infarction on magnetic resonance imaging as well as abnormal transcranial Doppler studies [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another series evaluated 2115 patients with Hb SS, Hb SC disease, Hb S-beta<sup>+</sup> thalassemia, or Hb S-beta<sup>0</sup> thalassemia [<a href="#rid33">33</a>]. The patients with Hb SS or Hb S-beta<sup>0</sup> thalassemia were consistently smaller and less sexually developed than those with Hb S-beta<sup>+</sup> thalassemia.</p><p></p><p>However, the genotype-phenotype correlations in Hb S-beta<sup>+</sup> thalassemia are variable, and a severe clinical course or life-threatening complications can be seen in patients with a milder beta thalassemic mutation. As an example, those with a beta mutation of IVS1-5(G--&gt;C) have a Hb A level less than 7 percent and manifestations of similar severity to Hb SS [<a href="#rid67">67</a>]. In Brazil, severe Hb S-beta<sup>+</sup> thalassemia accounted for almost half of this beta<sup>+</sup> group, and the average hemoglobin A was 4.5 percent, in contrast to 26 percent in mild Hb S-beta<sup>+</sup> thalassemia [<a href="#rid57">57</a>]. </p><p>Splenic dysfunction in Hb S-beta<sup>+</sup> thalassemia is less frequent in childhood but increases with age, resulting in 25 percent of adults having significant functional asplenia [<a href="#rid65">65</a>].</p><p>Hb S-beta<sup>+</sup> thalassemia is associated with anemia, microcytosis, and a Hb A fraction that ranges between 5 and 30 percent  (<a class="graphic graphic_table graphicRef116210" href="/z/d/graphic/116210.html" rel="external">table 1</a>). Neonates with sickle beta<sup>+</sup> thalassemia may have so little Hb A that the diagnosis of sickle beta<sup>0</sup> thalassemia is given. Family studies and more definitive testing are often indicated. </p><p class="headingAnchor" id="H3022347431"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment depends on disease severity, which is likely to correlate with the beta thalassemia variant (more severe with beta<sup>0</sup> variants and less severe with beta<sup>+</sup> variants). (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Sickle-alpha thalassemia</span><span class="headingEndMark"> — </span>Alpha thalassemia results from impaired production of alpha globin chains, which leads to a relative excess of beta globin chains. </p><p>A single alpha globin gene deletion, referred to as alpha thalassemia silent carrier, is present in more than 30 percent of SCD patients of African descent, with an even higher prevalence in some SCD populations in the Middle East and India. The peripheral blood smear contains less polychromasia and fewer sickled cells, and more hypochromia and microcytosis, commensurate with the number of alpha globin genes deleted. Hb A2 levels are increased according to the number of alpha globin gene deletions, while Hb F levels are not consistently affected [<a href="#rid68">68-71</a>]. The mean corpuscular volume is reduced and the degree of hemolysis and anemia is lessened [<a href="#rid72">72</a>]. </p><p>The effect of alpha thalassemia on the clinical course appears to have positive and negative effects: </p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with sickle cell-alpha thalassemia can have milder anemia, with fewer reticulocytes and sickled cells [<a href="#rid68">68-70,73</a>]. The toxicity of excess normal beta globin chains on the red cell membrane skeleton appears to be less than that of the excess partially oxidized alpha globin chains in beta thalassemia. This may be extrapolated to beta S chains to explain why the clinical manifestations are generally less severe in sickle cell-alpha thalassemia compared with sickle cell-beta thalassemia. (See  <a class="medical medical_review" href="/z/d/html/7090.html" rel="external">"Pathophysiology of thalassemia", section on 'Globin chain imbalance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The higher hemoglobin levels in some individuals with sickle-alpha thalassemia may contribute to hyperviscosity, which can increase symptoms. The higher hematocrit is still associated with Hb S-containing red cells, resulting in an overall increase in blood viscosity. This rise in hemoglobin and decreased hemolysis may decrease anemia and hemolysis-related events, while a higher hemoglobin level may increase the risk of some vaso-occlusion complications.</p><p></p><p>An early report suggested that coinheritance of alpha thalassemia was associated with longevity [<a href="#rid74">74</a>]; this conclusion was controversial [<a href="#rid34">34</a>]. Some studies have shown that the presence of alpha thalassemia and a reduction in intravascular hemolysis is associated with reduced mortality. </p><p>In other reports, the simultaneous presence of alpha thalassemia and SCD has been associated with the following effects:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in the extent of peripheral retinal vessel closure, without an effect on the frequency of proliferative sickle retinopathy [<a href="#rid75">75</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in the incidence of stroke in children [<a href="#rid76">76</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Protection against high cerebral blood velocities [<a href="#rid77">77,78</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in the incidence of leg ulcers [<a href="#rid31">31</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>In some children with high Hb F levels, alpha thalassemia appeared to preserve splenic function [<a href="#rid79">79</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Lower prevalence of glomerulopathy (macroalbuminuria) [<a href="#rid80">80</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced prevalence of priapism [<a href="#rid81">81</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced response to treatment with <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid82">82</a>]</p><p></p><p>However, not all population studies have shown a clinical benefit from the presence of alpha thalassemia. In a study from Jamaica, the absence of alpha thalassemia gene deletions influenced the clinical phenotype [<a href="#rid83">83</a>]. The best data on life expectancy come from the Cooperative Study of Sickle Cell disease, which found an increased mortality rate associated with higher hemoglobin levels after the age of 20 years [<a href="#rid25">25</a>].</p><p>These older studies regarding the clinical history of alpha globin gene deletion and its influence on SCD clinical history are quite limited because they do not reflect the influence of improved clinical management including conjugated vaccines, transcranial Doppler screening, and now four FDA-approved therapies. </p><p>Perhaps some of the discrepant results of earlier studies are a result of considering only the vaso-occlusive and viscosity-related complications of disease. Other studies suggest that intravascular hemolysis is closely associated with its own constellation of subphenotypes [<a href="#rid84">84</a>].</p><p>Studies of the effects of hemolysis on nitric oxide (NO) bioavailability suggest that alpha thalassemia protects against disease complications related to the intensity of hemolysis (eg, priapism, leg ulcers, stroke, and perhaps pulmonary hypertension) while increasing the risk of complications more directly related to blood viscosity (eg, painful episodes, acute chest syndrome, osteonecrosis) [<a href="#rid81">81</a>]. Patients with hyperhemolysis had higher systolic blood pressure, higher prevalence of leg ulcers, priapism, and pulmonary hypertension, while osteonecrosis and vaso-occlusive pain were less prevalent [<a href="#rid85">85</a>]. Hyperhemolysis was influenced by Hb F levels and the presence of alpha thalassemia, and was a risk factor for earlier death. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Impact of Hb F on sickle cell disease severity'</a> and  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Hyperhemolytic crisis'</a>.)</p><p>Due to the powerful effect of Hb S concentration upon Hb S polymerization, anemia is significantly milder in individuals with SCD and the deletion of either one (-a/aa) or two (-a/-a) alpha globin genes [<a href="#rid68">68-70,86,87</a>]. In one series, for example, the hemoglobin concentration was 9.8 g/dL in patients with Hb SS and the (-a/aa) genotype compared with 7.9 g/dL in those with Hb SS without alpha thalassemia [<a href="#rid68">68</a>]. These individuals have reduced hemolysis that is not demonstrable until approximately seven years of age [<a href="#rid86">86,87</a>].</p><p>Despite the improvement in anemia, the clinical effects of the interaction between SCD and alpha thalassemia are variable, due in part to the higher hemoglobin concentration and blood viscosity. While the overall clinical phenotype may be improved, there is not a definitive answer to the question of whether alpha thalassemia increases survival in patients with sickle cell anemia [<a href="#rid88">88,89</a>]. This is particularly true in the era of disease-modifying therapies. </p><p>This is illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of acute chest syndrome was decreased in one study and unchanged in another [<a href="#rid69">69,70</a>]. In a third report from the Cooperative Study of Sickle Cell disease, concurrent alpha thalassemia had no effect on the incidence of acute painful episodes apart from its association with higher hemoglobin concentrations [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a reduced incidence of leg ulcers (more in patients with two versus three alpha globin genes) [<a href="#rid31">31,69</a>]; the incidence of osteonecrosis is increased [<a href="#rid32">32,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of retinal vessel closure is reduced, but the risk of proliferative retinopathy is increased [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Sickle-hereditary persistence of fetal hemoglobin</span><span class="headingEndMark"> — </span>The physiologic switch from the production of fetal hemoglobin (Hb F: alpha2/gamma2) to adult hemoglobin (Hb A: alpha2/beta2) is usually completed by two years of age, resulting in a normal adult level of Hb F of &lt;1 percent. However, increased levels of Hb F can ameliorate the clinical course of disorders of beta globin gene expression including sickle cell disease (SCD) and beta thalassemia. (See  <a class="medical medical_review" href="/z/d/html/7090.html" rel="external">"Pathophysiology of thalassemia", section on 'Combinations of hemoglobin variants'</a>.)</p><p>In individuals with Hb SS, a Hb F level of 10 to 20 percent has been suggested as a threshold for diminished clinical severity [<a href="#rid92">92</a>], although some studies have suggested that any increment in Hb F may be clinically important [<a href="#rid34">34</a>]. Hb F in Hb SS usually consists of 4 percent to 10 percent of total hemoglobin. </p><p>In a group of disorders called hereditary persistence of fetal hemoglobin (HPFH), expression of the gamma globin gene persists at high levels in almost all of the adult red cells, referred to as pancellular Hb F distribution, with normal red blood cell indices and morphology. The gene frequency of the deletional HPFH locus is 0.0005 among African Americans, resulting in a calculated incidence of compound heterozygous sickle cell-deletional HPFH that is 1 percent that of SCD [<a href="#rid93">93</a>]. Sickle-HPFH may be more frequent than previously estimated [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Hereditary persistence of fetal hemoglobin (HPFH)'</a>.)</p><p>Individuals with compound heterozygosity for Hb S and HPFH have high concentrations of Hb S and 20 to 30 percent Hb F evenly distributed among red cells, are not anemic, and do not experience vaso-occlusive complications or other major complications of SCD [<a href="#rid95">95,96</a>]. </p><p>In individuals with Hb S-HPFH, hemoglobin analysis reveals only Hb S, Hb F, and Hb A2, which resembles sickle cell anemia, sickle cell-beta<sup>0</sup> thalassemia, and sickle cell-delta beta<sup>0</sup> thalassemia. Notable differences, however, are the markedly increased percentage of Hb F (10 to 40 percent) and Hb A2 levels &lt;2.5 percent (in contrast to the elevated levels in beta thalassemia) [<a href="#rid97">97,98</a>]. To avoid unnecessary over-treatment of this benign condition, genotypes should be determined in parents and especially in all children with high Hb F levels.</p><p>Sickle cell-deletional HPFH provided the first evidence that Hb F was a potent inhibitor of Hb S polymerization. Genetic modulation of the sickle cell anemia phenotype by Hb F as a strategy for cure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Gene therapy and gene editing'</a> and  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Sickle cell disease'</a> and  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p>In contrast, individuals with Hb SS and heterocellular Hb F distribution may have Hb F levels as high as 25 percent but may still have a clinical course similar to individuals with Hb SS who have lower Hb F levels, particularly as they become older [<a href="#rid99">99,100</a>]. Multiple genetic etiologies for elevated Hb F have been discussed, including beta-globin gene deletions or point mutations in the promoters of the gamma globin gene (<em>HBG1</em>). Unusually high Hb F can also be associated with variants of the major repressors of gamma globin expression, <em>BCL11A</em> and <em>MYB</em>. Perhaps most often, an explanation for very high Hb F levels in SCD is lacking. These conditions are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Hemoglobin switching and downregulation of Hb F expression'</a>.) </p><p class="headingAnchor" id="H10"><span class="h2">Sickle-delta beta(0) thalassemia</span><span class="headingEndMark"> — </span>The delta-beta (δβ) thalassemia variants usually are large deletions of the delta and beta globin genes. Unlike HPFH, these variants fail to block the switch from fetal to adult hemoglobin production. This allows an attempted switch from the expression of gamma globin to that of the deleted delta and beta genes. The uncommon compound heterozygous condition of Hb S delta-beta<sup>0</sup> thalassemia results in the presence of Hb S, Hb F, and Hb A2. The 15 to 25 percent Hb F is distributed in a heterocellular fashion. Anemia and reticulocytosis are mild, and clinical complications are infrequent [<a href="#rid101">101</a>]. Compound heterozygosity for delta-beta<sup>+</sup> thalassemia and the sickle mutation produces an even milder phenotype. (See <a class="local">'Unusual and confusing laboratory presentations for non-sickle cell disorders and suggestive of sickle cell trait'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h2">Sickle-Hb Lepore disease</span><span class="headingEndMark"> — </span>The Hb Lepore gene is a crossover fusion product of the delta and beta globin genes, the product of which, in the case of Hb Lepore Boston, has the same alkaline electrophoretic mobility as Hb S [<a href="#rid102">102</a>]. Because of the thalassemic expression of the fusion gene, individuals with simple heterozygosity for Hb Lepore Boston resemble sickle cell trait on hemoglobin electrophoresis, with only 12 percent of the mutant hemoglobin being present. (See  <a class="medical medical_review" href="/z/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes", section on 'Hb Lepore'</a>.)</p><p>The doubly heterozygous condition of sickle cell-Hb Lepore (Hb S-Lepore) is rare [<a href="#rid103">103</a>]. The peripheral smear shows microcytosis, hypochromia, and irreversibly sickled cells. Vaso-occlusive complications occur and splenomegaly is common [<a href="#rid104">104</a>].</p><p>Patients with this disorder resemble those with Hb SS or sickle cell-beta<sup>0</sup> thalassemia electrophoretically, but they have less severe anemia, similar to sickle cell-beta<sup>+</sup> thalassemia. However, a Hb Lepore band can be seen on cellulose acetate electrophoresis and more distinctly on high performance liquid chromatography (HPLC). The combination of predominantly Hb S with microcytosis suggests sickle cell-beta thalassemia, but the diagnosis of Hb S Lepore is suggested by the low to low normal Hb A2 levels that result from the incapacitation of one delta globin gene by the crossover. Hb F levels vary.</p><p class="headingAnchor" id="H12"><span class="h2">Sickle-Hb D disease</span><span class="headingEndMark"> — </span>The most common hemoglobin D variant, Hb D Los Angeles (<em>HBB</em> p.Glu121Gln, also called Hb D Punjab), is caused by a glutamic acid to glutamine substitution at codon 121 of the beta globin gene [<a href="#rid105">105</a>]. The glutamic acid to glutamine substitution appears to support the polymerization of Hb S [<a href="#rid106">106</a>]. (See  <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb D'</a>.)</p><p>Although asymptomatic in the heterozygous form, inheritance together with an Hb S allele (Hb SD disease) can result in a severe disease with clinical manifestations similar to homozygous SCD [<a href="#rid107">107</a>]. In a study of 42 patients in Iraq, painful events were the most common presentation, occurring in over 90 percent of children [<a href="#rid108">108</a>].<strong> </strong></p><p>Hb D Los Angeles has an electrophoretic mobility that is similar to Hb S under alkaline conditions. For this reason, Hb SD disease was first reported as an unusual case of sickle cell anemia [<a href="#rid109">109</a>]. Hb D can be distinguished from Hb S by acid electrophoresis or isoelectric focusing. There is moderately severe hemolytic anemia and the peripheral smear shows marked anisocytosis and poikilocytosis, target cells, and irreversibly sickled cells. Some children have severe disease similar to that of sickle cell anemia [<a href="#rid110">110,111</a>]. However, persistent splenomegaly is more common. </p><p class="headingAnchor" id="H13"><span class="h2">Sickle-Hb O Arab disease</span><span class="headingEndMark"> — </span>Hemoglobin O-Arab is another hemoglobinopathy due to a variant beta globin chain (<em>HBB</em> p.Glu121Lys). It was first described in an Israeli Arab family but its distribution is widespread [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb O-Arab'</a>.)</p><p>Sickle-Hb O Arab accounts for 5 percent of cases of SCD in Sudan and neighboring regions [<a href="#rid113">113</a>]. </p><p>Sickle cell-Hb O-Arab resembles Hb SC on alkaline electrophoresis, but Hb O-Arab can be distinguished from Hb C by either acid electrophoresis or isoelectric focusing. Hb O-Arab may be confused with Hb C-Harlem when Hb S is also present. The syndrome is characterized by moderately severe hemolytic anemia, and the peripheral smear shows anisocytosis, poikilocytosis and irreversibly sickled cells [<a href="#rid114">114,115</a>]. Oxygen affinity is reduced in sickle cell-Hb O-Arab compared with sickle cell anemia.</p><p>The clinical manifestations are severe and resemble those of homozygous sickle cell anemia. In one study of 13 patients, for example, all patients had significant sickling events including acute chest syndrome (11), recurrent painful episodes (10), nephropathy (four), aplastic crises (two), avascular necrosis (two), leg ulcers (two), and stroke (one) [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Sickle-Hb E disease</span><span class="headingEndMark"> — </span>Hb E (<em>HBB</em> p.glu26Lys) is a beta thalassemic hemoglobinopathy found predominantly in Southeast Asia. The mutant hemoglobin has an electrophoretic mobility similar to Hb C under alkaline conditions but can be resolved by acid electrophoresis or isoelectric focusing [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb E'</a>.)</p><p>The variant in codon 26 activates a cryptic splice site within the first intron of the beta globin gene, causing alternate splicing and decreased expression of the structural mutant [<a href="#rid117">117</a>]. As a result, Hb E comprises only 30 percent of the total hemoglobin in patients with compound heterozygosity for the Hb S and Hb E variants.</p><p>Heterozygotes and homozygotes for Hb E are asymptomatic with minimal anemia and microcytosis [<a href="#rid118">118</a>]. Hb SE disease may cause only mild hemolysis, no vaso-occlusive complications, and no remarkable abnormality of red blood cell morphology in those ≤18 years [<a href="#rid119">119</a>]. However, there are several case reports of more severe manifestations, such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria</p><p class="bulletIndent1"><span class="glyph">●</span>Splenic infarct during air travel [<a href="#rid120">120</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Acute chest syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Reversible bone marrow necrosis associated with parvovirus B19 infection [<a href="#rid121">121</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise-related death syndrome [<a href="#rid122">122</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Splenomegaly [<a href="#rid123">123</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cholelithiasis [<a href="#rid123">123</a>]</p><p></p><p>In one family, three siblings had moderately severe hemolysis, jaundice, bone pain, splenic infarction, recurrent pneumonia, and irreversibly sickled cells on the blood smear [<a href="#rid124">124</a>]. It has been suggested that patients with Hb SE disease be followed and managed in a similar fashion as those with Hb S beta<sup>+</sup> thalassemia and treated appropriately when they develop sickling-related symptoms and complications [<a href="#rid119">119</a>].</p><p class="headingAnchor" id="H1633741328"><span class="h1">SICKLE CELL SYNDROMES THAT APPEAR TO BE SICKLE CELL TRAIT ON HEMOGLOBIN ANALYSIS</span><span class="headingEndMark"> — </span>Depending on the geographic location, the prevalence of sickle cell trait (Hb AS) in newborns can be approximately 0.07 percent in the general United States population and 9 percent of African American births [<a href="#rid125">125</a>]. The prevalence is 30 percent of the births in West Africa [<a href="#rid126">126</a>]. (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Genetics'</a>.)</p><p>In individuals suspected of having sickle cell trait, the hemoglobin and red blood cell (RBC) parameters are expected to be normal, and these individuals are expected to have a normal life-expectancy, with rare clinical events only seen in extreme physical conditions [<a href="#rid125">125</a>]. There is also a high relative risk (but low absolute risk) of renal cell carcinoma (RCC). (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Urologic and kidney disease'</a>.)</p><p>However, a very small subset of individuals with a Hb AS pattern will have clinical symptoms typically associated with sickle cell disease (SCD). These individuals should be evaluated for rare syndromes that have a clinical phenotype associated with SCD. At least 14 different clinically relevant sickling Hb variants other than Hb S have been described [<a href="#rid127">127</a>]. Two examples are Hb S-Jamaica Plain and Hb S with pyruvate kinase deficiency. (See <a class="local">'Hb S-Jamaica plain'</a> below and <a class="local">'Hb S plus pyruvate kinase deficiency'</a> below.)</p><p>These rare SCD syndromes are difficult to diagnosis and are often missed because high-performance liquid chromatography (HPLC) reveals a majority of hemoglobin A. The total hemoglobin levels are low but often not low enough to prompt an extensive evaluation. These compound heterozygotes are heterozygous for both the sickle cell variant and a second beta globin variant. The clinical manifestations can vary considerably, including clinical phenotypes that mimic SCD, such as Hb S-Oman, Hb S-Antilles, Hb S-Jamaica Plain, and Hb S-São Paulo [<a href="#rid128">128</a>]. </p><p class="headingAnchor" id="H3788522403"><span class="h2">Hb S-Jamaica plain</span><span class="headingEndMark"> — </span>In Hb S-Jamaica Plain, the proband has Hb AS on HPLC and is heterozygous for the sickle cell variant. They also have a second, charge-neutral beta globin variant, Leu68Phe. This hemoglobin was studied and noted to have severely reduced oxygen affinity, and structural modeling suggested destabilization of the oxy conformation as a molecular mechanism for sickling in a heterozygote at normal oxygen pressure [<a href="#rid129">129</a>]. Following splenectomy, laboratory values included a hemoglobin of 8.0 g/dL and a mean corpuscular volume (MCV) of 80.4 fL. HPLC showed Hb A &gt;60 percent, with 25 to 40 percent Hb S, 2.1 to 3.1 percent Hb A2, and 2.7 to 13 percent Hb F.</p><p class="headingAnchor" id="H1146169338"><span class="h2">Hb S plus pyruvate kinase deficiency</span><span class="headingEndMark"> — </span>The SCD phenotype has also be seen in a compound heterozygote for the sickle cell variant and a variant that causes pyruvate kinase (PK) deficiency. A case report described a female who had recurrent acute vaso-occlusive pain episodes and leg ulcers, clinical features typically associated with SCD [<a href="#rid130">130</a>]. The authors postulated that decreased oxygen affinity associated with PK deficiency caused clinical features of SCD. Her baseline laboratory parameters revealed Hb 9.8 g/dL, and MCV 88.7 fL. Her blood smear revealed a few sickle cells. HPLC showed 62 percent Hb A, 35 percent Hb S, 2 to 3 percent Hb A2, and 0.4 percent Hb F. </p><p class="headingAnchor" id="H2149864009"><span class="h2">Two variants on one beta globin gene</span><span class="headingEndMark"> — </span>Another example of SCD in heterozygotes occurs when there are two separate variants affecting the <strong>same </strong>beta globin chain. (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Symptoms of sickle cell disease'</a>.)</p><p>The two most common types of variants are Hb S-Antilles and Hb S-Oman. Heterozygotes for Hb S-Antilles have a mild hemolytic anemia with sickle cells on the blood smear. These individuals may also develop painful episodes and other symptoms [<a href="#rid131">131</a>]. On hemoglobin electrophoresis, these conditions may appear as sickle trait. Additional molecular and DNA techniques are required to make these diagnoses. (See  <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a>.)</p><p class="headingAnchor" id="H2264334889"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">"Patient perspective: Sickle cell disease"</a>.)</p><p class="headingAnchor" id="H22112655"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – There are a variety of sickle cell disease (SCD) syndromes that result from inheritance of the sickle cell variant in compound heterozygosity with other beta globin gene variants  (<a class="graphic graphic_table graphicRef116210" href="/z/d/graphic/116210.html" rel="external">table 1</a>). Sickle cell trait is not a sickle cell disease syndrome. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin SC disease (Hb SC</strong>) – Individuals with Hb SC disease are at risk for the same complications as those with Hb SS disease but at a decreased frequency. Anemia is mild, and splenomegaly may be the only finding on physical examination. The blood smear shows target cells, folded cells, occasional irreversibly sickled cells, and occasional cells containing hemoglobin crystals. Hb S and Hb C are seen in equal amounts on electrophoresis. (See <a class="local">'Hb SC disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb S-beta</strong><strong><sup>0</sup></strong><strong> thalassemia</strong> – Individuals with Hb S-beta<sup>0</sup> thalassemia have severe disease that may be somewhat less severe than Hb SS disease. This variant is more common in the Greek and Mediterranean regions than in the African American population. No Hb A is present on electrophoresis. It is distinguished from Hb SS disease by the presence of hypochromic, microcytic red cells and increased levels of Hb A2. Management is similar to individuals with homozygous SCD (Hb SS). (See <a class="local">'Sickle-beta thalassemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb S-beta</strong><strong><sup>+</sup></strong><strong> thalassemia</strong> – Individuals with Hb S-beta<sup>+</sup> thalassemia have a form of SCD that is less severe than Hb SS disease. Disease severity is inversely related to the amount of Hb A present, which varies from 5 to 30 percent. The peripheral smear shows the presence of hypochromic, microcytic red cells, and levels of Hb A2 are increased. Management is individualized depending on the patient's clinical course. (See <a class="local">'Sickle-beta thalassemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb SS with alpha thalassemia</strong> – The clinical manifestations and degree of anemia in Hb SS with alpha thalassemia are generally less severe than those seen in Hb S-beta<sup>0</sup> thalassemia. Hb A2 levels are increased according to the number of alpha globin gene deletions. Clinically, a distinction between Hb SS with alpha thalassemia and without alpha thalassemia is not required. (See <a class="local">'Sickle-alpha thalassemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle hereditary persistence of fetal hemoglobin (sickle HPFH)</strong> – Individuals with pancellular sickle HPFH are not anemic, do not experience vaso-occlusive episodes, and may have Hb F levels as high as 35 percent. (See <a class="local">'Sickle-hereditary persistence of fetal hemoglobin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other variants </strong>– Other sickle cell syndrome variants such as sickle-delta beta<sup>0</sup> thalassemia, Hb S-Lepore, Hb SD, Hb S-O Arab, Hb SE, and variants that cause SCD in heterozygotes are less common and are discussed in the text above. (See <a class="local">'Sickle-Hb Lepore disease'</a> above and <a class="local">'Sickle-Hb D disease'</a> above and <a class="local">'Sickle-Hb O Arab disease'</a> above and <a class="local">'Sickle-Hb E disease'</a> above and <a class="local">'Sickle cell syndromes that appear to be sickle cell trait on hemoglobin analysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and management</strong> – The diagnosis, clinical manifestations, and management of sickle cell trait and SCD are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait"</a> and  <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a> and  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a> and  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H3413877966"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges extensive contributions of Donald H Mahoney, Jr, MD to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.</a></li><li><a class="nounderline abstract_t">Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.</a></li><li><a class="nounderline abstract_t">DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv 2020; 4:1554.</a></li><li><a class="nounderline abstract_t">AlRyalat SA, Jaber BAM, Alzarea AA, et al. Ocular Manifestations of Sickle Cell Disease in Different Genotypes. Ophthalmic Epidemiol 2021; 28:185.</a></li><li><a class="nounderline abstract_t">Sahak H, Saqalain M, Lott PW, McKibbin M. Sickle Cell Maculopathy: Prevalence, Associations and Impact on Visual Acuity. Ophthalmologica 2021; 244:159.</a></li><li><a class="nounderline abstract_t">Arlet JB, de Luna G, Khimoud D, et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol 2020; 7:e632.</a></li><li><a class="nounderline abstract_t">Elenga N, Celicourt D, Muanza B, et al. Dengue in hospitalized children with sickle cell disease: A retrospective cohort study in the French departments of America. J Infect Public Health 2020; 13:186.</a></li><li><a class="nounderline abstract_t">Elenga N, Nacher M, Trehan I. The Imperative of Dengue Vaccination for Children with Sickle Cell Disease. J Trop Pediatr 2020; 66:245.</a></li><li><a class="nounderline abstract_t">Minniti CP, Zaidi AU, Nouraie M, et al. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv 2021; 5:207.</a></li><li><a class="nounderline abstract_t">Ibemere SO, Oyedeji CI, Preiss L, et al. Characterising the prevalence of overweight and obese status among adults with sickle cell disease. Br J Haematol 2023; 200:633.</a></li><li><a class="nounderline abstract_t">Shook LM, Haygood D, Quinn CT. Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening. Int J Neonatal Screen 2020; 6.</a></li><li><a class="nounderline abstract_t">Zertal-Zidani S, Ducrocq R, Weil-Olivier C, et al. A novel delta beta fusion gene expresses hemoglobin A (HbA) not Hb Lepore: Senegalese delta(0)beta(+) thalassemia. Blood 2001; 98:1261.</a></li><li><a class="nounderline abstract_t">Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973; 288:31.</a></li><li><a class="nounderline abstract_t">Bunn HF, Noguchi CT, Hofrichter J, et al. Molecular and cellular pathogenesis of hemoglobin SC disease. Proc Natl Acad Sci U S A 1982; 79:7527.</a></li><li><a class="nounderline abstract_t">Hirsch RE, Raventos-Suarez C, Olson JA, Nagel RL. Ligand state of intraerythrocytic circulating HbC crystals in homozygote CC patients. Blood 1985; 66:775.</a></li><li><a class="nounderline abstract_t">Fabry ME, Kaul DK, Raventos-Suarez C, et al. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences. J Clin Invest 1982; 70:1315.</a></li><li><a class="nounderline abstract_t">Ballas SK, Lewis CN, Noone AM, et al. Clinical, hematological, and biochemical features of Hb SC disease. Am J Hematol 1982; 13:37.</a></li><li><a class="nounderline abstract_t">RIVER GL, ROBBINS AB, SCHWARTZ SO. S-C hemoglobin: a clinical study. Blood 1961; 18:385.</a></li><li><a class="nounderline abstract_t">Lawrence C, Fabry ME, Nagel RL. The unique red cell heterogeneity of SC disease: crystal formation, dense reticulocytes, and unusual morphology. Blood 1991; 78:2104.</a></li><li><a class="nounderline abstract_t">da Guarda CC, Yahouédéhou SCMA, Santiago RP, et al. Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC). PLoS One 2020; 15:e0228399.</a></li><li><a class="nounderline abstract_t">West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992; 45:893.</a></li><li><a class="nounderline abstract_t">McCurdy PR. 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes. Blood 1969; 33:214.</a></li><li><a class="nounderline abstract_t">Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell disease complications: a clinical study of 179 cases. Haematologica 2012; 97:1136.</a></li><li><a class="nounderline abstract_t">Minniti C, Brugnara C, Steinberg MH. HbSC disease: A time for progress. Am J Hematol 2022; 97:1390.</a></li><li><a class="nounderline abstract_t">Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.</a></li><li><a class="nounderline abstract_t">Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996; 17:965.</a></li><li><a class="nounderline abstract_t">Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.</a></li><li><a class="nounderline abstract_t">Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 1991; 115:614.</a></li><li><a class="nounderline abstract_t">Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109:579.</a></li><li><a class="nounderline abstract_t">Buchanan GR, Smith SJ, Holtkamp CA, Fuseler JP. Bacterial infection and splenic reticuloendothelial function in children with hemoglobin SC disease. Pediatrics 1983; 72:93.</a></li><li><a class="nounderline abstract_t">Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74:1403.</a></li><li><a class="nounderline abstract_t">Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325:1476.</a></li><li><a class="nounderline abstract_t">Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 1984; 311:7.</a></li><li><a class="nounderline abstract_t">Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.</a></li><li><a class="nounderline abstract_t">Asare EV, Olayemi E, Boafor T, et al. Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD. Am J Hematol 2019; 94:E328.</a></li><li><a class="nounderline abstract_t">Oppong SA, Asare EV, Olayemi E, et al. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting. Am J Hematol 2019; 94:223.</a></li><li><a class="nounderline abstract_t">Condon PI, Hayes RJ, Serjeant GR. Retinal and choroidal neovascularization in sickle cell disease. Trans Ophthalmol Soc U K 1980; 100:434.</a></li><li><a class="nounderline abstract_t">Scheifer C, Lionnet F, Bachmeyer C, et al. Cerebral Fat Embolism in Hemoglobin SC Disease. Am J Med 2017; 130:e187.</a></li><li><a class="nounderline abstract_t">Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 2015; 125:3316.</a></li><li><a class="nounderline abstract_t">Drawz P, Ayyappan S, Nouraie M, et al. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. Clin J Am Soc Nephrol 2016; 11:207.</a></li><li><a class="nounderline abstract_t">Colella MP, de Paula EV, Machado-Neto JA, et al. Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica 2015; 100:466.</a></li><li><a class="nounderline abstract_t">Gualandro SF, Fonseca GH, Yokomizo IK, et al. Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality. Br J Haematol 2015; 171:631.</a></li><li><a class="nounderline abstract_t">Thame MM, Singh-Minott I, Osmond C, et al. Pregnancy in sickle cell-haemoglobin C (SC) disease. A retrospective study of birth size and maternal weight gain. Eur J Obstet Gynecol Reprod Biol 2016; 203:16.</a></li><li><a class="nounderline abstract_t">Pecker LH, Schaefer BA, Luchtman-Jones L. Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol 2017; 176:515.</a></li><li><a class="nounderline abstract_t">Summarell CC, Sheehan VA. Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. Exp Biol Med (Maywood) 2016; 241:737.</a></li><li><a class="nounderline abstract_t">Luchtman-Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol 2016; 91:238.</a></li><li><a class="nounderline abstract_t">Padaro E, Kueviakoe IMD, Agbétiafa K, et al. Therapeutic phlebotomy during major sickle cell disease in Togo. Med Sante Trop 2019; 29:106.</a></li><li><a class="nounderline abstract_t">Markham MJ, Lottenberg R, Zumberg M. Role of phlebotomy in the management of hemoglobin SC disease: case report and review of the literature. Am J Hematol 2003; 73:121.</a></li><li><a class="nounderline abstract_t">Lane PA, O'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. Blood 1995; 85:2238.</a></li><li><a class="nounderline abstract_t">Orringer EP, Fowler VG Jr, Owens CM, et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease. Am J Med Sci 1991; 302:374.</a></li><li><a class="nounderline abstract_t">Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486.</a></li><li><a class="nounderline abstract_t">SINGER K, SINGER L, GOLDBERG SR. Studies on abnormal hemoglobins. XI. Sickle cell-thalassemia disease in the Negro; the significance of the S+A+F and S+A patterns obtained by hemoglobin analysis. Blood 1955; 10:405.</a></li><li><a class="nounderline abstract_t">SMITH EW, CONLEY CL. Clinical features of the genetic variants of sickle cell disease. Bull Johns Hopkins Hosp 1954; 94:289.</a></li><li><a class="nounderline abstract_t">Gonzalez-Redondo JM, Stoming TA, Lanclos KD, et al. Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States. Blood 1988; 72:1007.</a></li><li><a class="nounderline abstract_t">Gonzalez-Redondo JM, Kutlar A, Kutlar F, et al. Molecular characterization of Hb S(C) beta-thalassemia in American blacks. Am J Hematol 1991; 38:9.</a></li><li><a class="nounderline abstract_t">Christakis J, Vavatsi N, Hassapopoulou H, et al. A comparison of sickle cell syndromes in northern Greece. Br J Haematol 1991; 77:386.</a></li><li><a class="nounderline abstract_t">Belisário AR, Carneiro-Proietti AB, Sabino EC, et al. Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics. Hemoglobin 2020; 44:1.</a></li><li><a class="nounderline abstract_t">Day ME, Rodeghier M, Driggers J, et al. A significant proportion of children of African descent with HbSβ0 thalassaemia are inaccurately diagnosed based on phenotypic analyses alone. Br J Haematol 2019; 185:153.</a></li><li><a class="nounderline abstract_t">Serjeant GR, Sommereux AM, Stevenson M, et al. Comparison of sickle cell-beta0 thalassaemia with homozygous sickle cell disease. Br J Haematol 1979; 41:83.</a></li><li><a class="nounderline abstract_t">Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643.</a></li><li><a class="nounderline abstract_t">Voskaridou E, Tsetsos G, Tsoutsias A, et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007; 92:738.</a></li><li><a class="nounderline abstract_t">Rigano P, Pecoraro A, Calvaruso G, et al. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. Am J Hematol 2013; 88:E261.</a></li><li><a class="nounderline abstract_t">Zafeiriou DI, Prengler M, Gombakis N, et al. Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia. Ann Neurol 2004; 55:835.</a></li><li><a class="nounderline abstract_t">Day ME, Rodeghier M, DeBaun MR. Children with HbSβ0 thalassemia have higher hemoglobin levels and lower incidence rate of acute chest syndrome compared to children with HbSS. Pediatr Blood Cancer 2018; 65:e27352.</a></li><li><a class="nounderline abstract_t">Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985; 76:392.</a></li><li class="breakAll">Serjeant GR, Serjeant BE. Comparison of sickle cell-bº thalassemia and sickle cell-b+ thalassemia in Black populations. In: Thalassemia: Advances in detection and treatment, Birth Defects Original Article Series, Cao A, Carcassi U, Rowley PT (Eds), Alan R Liss, New York 1982. p.233.</li><li><a class="nounderline abstract_t">Sweeting I, Serjeant BE, Thomas PW, Serjeant GR. Microchromatographic quantitation of hemoglobin A levels in phenotypes of sickle cell-beta(+) thalassemia. J Chromatogr B Biomed Sci Appl 1997; 700:269.</a></li><li><a class="nounderline abstract_t">Embury SH, Dozy AM, Miller J, et al. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 1982; 306:270.</a></li><li><a class="nounderline abstract_t">Higgs DR, Aldridge BE, Lamb J, et al. The interaction of alpha-thalassemia and homozygous sickle-cell disease. N Engl J Med 1982; 306:1441.</a></li><li><a class="nounderline abstract_t">Steinberg MH, Rosenstock W, Coleman MB, et al. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 1984; 63:1353.</a></li><li><a class="nounderline abstract_t">Dover GJ, Chang VT, Boyer SH, et al. The cellular basis for different fetal hemoglobin levels among sickle cell individuals with two, three, and four alpha-globin genes. Blood 1987; 69:341.</a></li><li><a class="nounderline abstract_t">Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68:985.</a></li><li><a class="nounderline abstract_t">Embury SH, Clark MR, Monroy G, Mohandas N. Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes. J Clin Invest 1984; 73:116.</a></li><li><a class="nounderline abstract_t">Mears JG, Lachman HM, Labie D, Nagel RL. Alpha-thalassemia is related to prolonged survival in sickle cell anemia. Blood 1983; 62:286.</a></li><li><a class="nounderline abstract_t">Fox PD, Higgs DR, Serjeant GR. Influence of alpha thalassaemia on the retinopathy of homozygous sickle cell disease. Br J Ophthalmol 1993; 77:89.</a></li><li><a class="nounderline abstract_t">Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol 1994; 45:279.</a></li><li><a class="nounderline abstract_t">Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 2008; 112:4314.</a></li><li><a class="nounderline abstract_t">Rees DC, Lambert C, Cooper E, et al. Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. Blood 2009; 114:742.</a></li><li><a class="nounderline abstract_t">Adekile AD, Tuli M, Haider MZ, et al. Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Am J Hematol 1996; 53:1.</a></li><li><a class="nounderline abstract_t">Guasch A, Zayas CF, Eckman JR, et al. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. J Am Soc Nephrol 1999; 10:1014.</a></li><li><a class="nounderline abstract_t">Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005; 106:3264.</a></li><li><a class="nounderline abstract_t">Vasavda N, Badiger S, Rees D, et al. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. Br J Haematol 2008; 143:589.</a></li><li><a class="nounderline abstract_t">Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 2004; 126:606.</a></li><li><a class="nounderline abstract_t">Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 2017; 127:750.</a></li><li><a class="nounderline abstract_t">Taylor JG 6th, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008; 3:e2095.</a></li><li><a class="nounderline abstract_t">de Ceulaer K, Higgs DR, Weatherall DJ, et al. alpha-Thalassemia reduces the hemolytic rate in homozygous sickle-cell disease. N Engl J Med 1983; 309:189.</a></li><li><a class="nounderline abstract_t">Stevens MC, Maude GH, Beckford M, et al. Alpha thalassemia and the hematology of homozygous sickle cell disease in childhood. Blood 1986; 67:411.</a></li><li><a class="nounderline abstract_t">Thomas PW, Higgs DR, Serjeant GR. Benign clinical course in homozygous sickle cell disease: a search for predictors. J Clin Epidemiol 1997; 50:121.</a></li><li><a class="nounderline abstract_t">Kéclard L, Romana M, Lavocat E, et al. Sickle cell disorder, beta-globin gene cluster haplotypes and alpha-thalassemia in neonates and adults from Guadeloupe. Am J Hematol 1997; 55:24.</a></li><li><a class="nounderline abstract_t">Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res 1993; :136.</a></li><li><a class="nounderline abstract_t">Fox PD, Dunn DT, Morris JS, Serjeant GR. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol 1990; 74:172.</a></li><li><a class="nounderline abstract_t">Marcus SJ, Kinney TR, Schultz WH, et al. Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. Am J Hematol 1997; 54:40.</a></li><li><a class="nounderline abstract_t">Bradley TB, Brawner JN, Conley CL. Further observations on an inherited anomaly characterized by persisetnce of fetal hemoglobin. Bull Johns Hopk Hosp 1961; 108:242.</a></li><li><a class="nounderline abstract_t">Serjeant GR, Serjeant BE, Hambleton IR, et al. A Plea for the Newborn Diagnosis of Hb S-Hereditary Persistence of Fetal Hemoglobin. Hemoglobin 2017; 41:216.</a></li><li><a class="nounderline abstract_t">CONLEY CL, WEATHERALL DJ, RICHARDSON SN, et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 1963; 21:261.</a></li><li><a class="nounderline abstract_t">Steinberg MH. Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Murray N, Serjeant BE, Serjeant GR. Sickle cell-hereditary persistence of fetal haemoglobin and its differentiation from other sickle cell syndromes. Br J Haematol 1988; 69:89.</a></li><li><a class="nounderline abstract_t">Ngo DA, Aygun B, Akinsheye I, et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol 2012; 156:259.</a></li><li><a class="nounderline abstract_t">Powars DR, Schroeder WA, Weiss JN, et al. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest 1980; 65:732.</a></li><li><a class="nounderline abstract_t">Adekile AD. Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients. Hemoglobin 2011; 35:607.</a></li><li><a class="nounderline abstract_t">Kinney TR, Friedman S, Cifuentes E, et al. Variations in globin synthesis in delta-beta-thalassaemia. Br J Haematol 1978; 38:15.</a></li><li><a class="nounderline abstract_t">O'Reilly RA. A kindred with hemoglobin Lepore. JAMA 1976; 236:478.</a></li><li><a class="nounderline abstract_t">Seward DP, Ware RE, Kinney TR. Hemoglobin sickle-Lepore: report of two siblings and review of the literature. Am J Hematol 1993; 44:192.</a></li><li><a class="nounderline abstract_t">Stevens MC, Lehmann H, Mason KP, et al. Sickle cell-Hb Lepore Boston syndrome. Uncommon differential diagnosis to homozygous sickle cell disease. Am J Dis Child 1982; 136:19.</a></li><li><a class="nounderline abstract_t">Schnee J, Aulehla-Scholz C, Eigel A, Horst J. Hb D Los Angeles (D-Punjab) and Hb Presbyterian: analysis of the defect at the DNA level. Hum Genet 1990; 84:365.</a></li><li><a class="nounderline abstract_t">Adachi K, Kim J, Ballas S, et al. Facilitation of Hb S polymerization by the substitution of Glu for Gln at beta 121. J Biol Chem 1988; 263:5607.</a></li><li><a class="nounderline abstract_t">STURGEON P, ITANO HA, BERGREN WR. Clinical manifestations of inherited abnormal hemoglobins. I. The interaction of hemoglobin-S with hemoglobin-D. Blood 1955; 10:389.</a></li><li><a class="nounderline abstract_t">Zuhair Abd Ali, Subeh Salim Abdulateef, Meaad Kadhum Hassan, Rawshan Zuhair Jaber. Double heterozygosity for hemoglobin S and D Punjab in Basra, Iraq: A Clinical and hematological study of 42 patients. Journal of Applied Hematology 2019; 10:134.</a></li><li><a class="nounderline abstract_t">Cooke JV, Mack JK. Sickle-cell anemia in a white American family. J Pediatr 1934; 5:601.</a></li><li><a class="nounderline abstract_t">Kelleher JF Jr, Park JO, Kim HC, Schroeder WA. Life-threatening complications in a child with hemoglobin SD-Los Angeles disease. Hemoglobin 1984; 8:203.</a></li><li><a class="nounderline abstract_t">Schmugge M, Frischknecht H, Yonekawa Y, et al. Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery. Blood 2001; 97:2165.</a></li><li><a class="nounderline abstract_t">Ramot B, Fisher S, Remez D, et al. Haemoglobin O in An Arab Family. Br Med J 1960; 2:1262.</a></li><li><a class="nounderline abstract_t">Elbashir I, Elsayed Yousif TY. Molecular Detection of Hemoglobin O-Arab in the Sudanese Population. Int J Gen Med 2023; 16:3323.</a></li><li><a class="nounderline abstract_t">Milner PF, Miller C, Grey R, et al. Hemoglobin O arab in four negro families and its interaction with hemoglobin S and hemoglobin C. N Engl J Med 1970; 283:1417.</a></li><li><a class="nounderline abstract_t">Zimmerman SA, O'Branski EE, Rosse WF, Ware RE. Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Am J Hematol 1999; 60:279.</a></li><li><a class="nounderline abstract_t">CHERNOFF AI, MINNICH V, CHONGCHAREONSUK S. Hemoglobin E, a hereditary abnormality of human hemoglobin. Science 1954; 120:605.</a></li><li><a class="nounderline abstract_t">Orkin SH, Kazazian HH Jr, Antonarakis SE, et al. Abnormal RNA processing due to the exon mutation of beta E-globin gene. Nature 1982; 300:768.</a></li><li><a class="nounderline abstract_t">Rees DC, Styles L, Vichinsky EP, et al. The hemoglobin E syndromes. Ann N Y Acad Sci 1998; 850:334.</a></li><li><a class="nounderline abstract_t">Masiello D, Heeney MM, Adewoye AH, et al. Hemoglobin SE disease: a concise review. Am J Hematol 2007; 82:643.</a></li><li><a class="nounderline abstract_t">Schroeder WA, Powars D, Reynolds RD, Fisher JI. Hb-E in combination with Hb-S and Hb-C in a black family. Hemoglobin 1977; 1:287.</a></li><li><a class="nounderline abstract_t">Eichhorn RF, Buurke EJ, Blok P, et al. Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. J Intern Med 1999; 245:103.</a></li><li><a class="nounderline abstract_t">Arbefeville EF, Tebbi CK, Chrostowski L, Adams VI. Sudden death after exercise in an adolescent with hemoglobin SE. Am J Forensic Med Pathol 2011; 32:341.</a></li><li><a class="nounderline abstract_t">Basu T, Das M, Sengupta M, Mallik Sinha MG. Clinico-Hematological Profile in Hemoglobin SE Disease: A Case Series from a Tertiary Care Centre. Indian J Hematol Blood Transfus 2023; 39:495.</a></li><li><a class="nounderline abstract_t">Rosenberg MR. In vivo and in vitro interactions of human haemoglobins A,S and C with a variant haemoglobin E. Nature 1968; 219:1042.</a></li><li><a class="nounderline abstract_t">Ojodu J, Hulihan MM, Pope SN, et al. Incidence of sickle cell trait--United States, 2010. MMWR Morb Mortal Wkly Rep 2014; 63:1155.</a></li><li class="breakAll">Sickle-cell disease: a strategy for the WHO African region. World Health Organization Regional Committee for Africa. Available at: apps.who.int/iris/bitstream/10665/1682/1/AFR-RC60-8.pdf (Accessed on February 01, 2018).</li><li><a class="nounderline abstract_t">Ahmed SG, Ibrahim UA. Non-S Sickling Hemoglobin Variants: Historical, Genetic, Diagnostic, and Clinical Perspectives. Oman Med J 2021; 36:e261.</a></li><li><a class="nounderline abstract_t">Nagel RL, Daar S, Romero JR, et al. HbS-oman heterozygote: a new dominant sickle syndrome. Blood 1998; 92:4375.</a></li><li><a class="nounderline abstract_t">Geva A, Clark JJ, Zhang Y, et al. Hemoglobin Jamaica plain--a sickling hemoglobin with reduced oxygen affinity. N Engl J Med 2004; 351:1532.</a></li><li><a class="nounderline abstract_t">Alli N, Coetzee M, Louw V, et al. Sickle cell disease in a carrier with pyruvate kinase deficiency. Hematology 2008; 13:369.</a></li><li><a class="nounderline abstract_t">Monplaisir N, Merault G, Poyart C, et al. Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes. Proc Natl Acad Sci U S A 1986; 83:9363.</a></li></ol></div><div id="topicVersionRevision">Topic 7115 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9287233" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathogenesis and treatment of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675655" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298430" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757703" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ocular Manifestations of Sickle Cell Disease in Different Genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33120391" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sickle Cell Maculopathy: Prevalence, Associations and Impact on Visual Acuity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32563282" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognosis of patients with sickle cell disease and COVID-19: a French experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548164" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dengue in hospitalized children with sickle cell disease: A retrospective cohort study in the French departments of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32357242" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Imperative of Dengue Vaccination for Children with Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570644" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36382420" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characterising the prevalence of overweight and obese status among adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32064363" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493481" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A novel delta beta fusion gene expresses hemoglobin A (HbA) not Hb Lepore: Senegalese delta(0)beta(+) thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4681897" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Frequency of sickling disorders in U.S. blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6961429" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular and cellular pathogenesis of hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2412615" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ligand state of intraerythrocytic circulating HbC crystals in homozygote CC patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7174796" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7137165" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical, hematological, and biochemical features of Hb SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14492555" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : S-C hemoglobin: a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1912587" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The unique red cell heterogeneity of SC disease: crystal formation, dense reticulocytes, and unusual morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31995624" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1624972" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5766311" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315500" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemoglobin sickle cell disease complications: a clinical study of 179 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36073655" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : HbSC disease: A time for progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1710777" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pain in sickle cell disease. Rates and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733975" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9414296" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cerebrovascular accidents in sickle cell disease: rates and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1892333" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3531449" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bacteremia in sickle hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6602968" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bacterial infection and splenic reticuloendothelial function in children with hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475188" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Leg ulcers in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944426" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sickle cell disease as a cause of osteonecrosis of the femoral head.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727978" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Influence of sickle hemoglobinopathies on growth and development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993409" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mortality in sickle cell disease. Life expectancy and risk factors for early death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571271" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30456766" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6171076" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Retinal and choroidal neovascularization in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28189467" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cerebral Fat Embolism in Hemoglobin SC Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800049" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26672090" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596272" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Elevated hypercoagulability markers in hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26255986" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235631" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pregnancy in sickle cell-haemoglobin C (SC) disease. A retrospective study of birth size and maternal weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27982424" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Knowledge insufficient: the management of haemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26993671" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26615793" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of hydroxyurea treatment for patients with hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31031233" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Therapeutic phlebotomy during major sickle cell disease in Togo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12749014" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of phlebotomy in the management of hemoglobin SC disease: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718896" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Functional asplenia in hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1772123" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061217" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Newborn screening for hemoglobinopathies in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14363321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Studies on abnormal hemoglobins. XI. Sickle cell-thalassemia disease in the Negro; the significance of the S+A+F and S+A patterns obtained by hemoglobin analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13160682" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical features of the genetic variants of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2458145" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1897518" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Molecular characterization of Hb S(C) beta-thalassemia in American blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012764" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A comparison of sickle cell syndromes in northern Greece.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172616" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29797315" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A significant proportion of children of African descent with HbSβ0 thalassaemia are inaccurately diagnosed based on phenotypic analyses alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/420738" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of sickle cell-beta0 thalassaemia with homozygous sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7517723" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550845" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828131" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15174017" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30094930" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Children with HbSβ0 thalassemia have higher hemoglobin levels and lower incidence rate of acute chest syndrome compared to children with HbSS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2412200" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Developmental pattern of splenic dysfunction in sickle cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2412200" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Developmental pattern of splenic dysfunction in sickle cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390739" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Microchromatographic quantitation of hemoglobin A levels in phenotypes of sickle cell-beta(+) thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6172710" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6176865" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The interaction of alpha-thalassemia and homozygous sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6722353" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2431731" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The cellular basis for different fetal hemoglobin levels among sickle cell individuals with two, three, and four alpha-globin genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3533181" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6690472" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6307429" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Alpha-thalassemia is related to prolonged survival in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435425" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Influence of alpha thalassaemia on the retinopathy of homozygous sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178798" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Alpha thalassemia and stroke risk in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18772456" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608759" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813088" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232687" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985542" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hemolysis-associated priapism in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18764867" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15287956" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Are there clinical phenotypes of homozygous sickle cell disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28248201" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Intravascular hemolysis and the pathophysiology of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18461136" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866027" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : alpha-Thalassemia reduces the hemolytic rate in homozygous sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2417644" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Alpha thalassemia and the hematology of homozygous sickle cell disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120504" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Benign clinical course in homozygous sickle cell disease: a search for predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9136913" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sickle cell disorder, beta-globin gene cluster haplotypes and alpha-thalassemia in neonates and adults from Guadeloupe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8472404" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Osteonecrosis of the humeral head in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2322516" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Risk factors for proliferative sickle retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980259" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Further observations on an inherited anomaly characterized by persisetnce of fetal hemoglobin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28870138" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A Plea for the Newborn Diagnosis of Hb S-Hereditary Persistence of Fetal Hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14022587" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33238542" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2454649" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Sickle cell-hereditary persistence of fetal haemoglobin and its differentiation from other sickle cell syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017641" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6153392" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21999156" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/638060" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Variations in globin synthesis in delta-beta-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/947069" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A kindred with hemoglobin Lepore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213769" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hemoglobin sickle-Lepore: report of two siblings and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055103" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sickle cell-Hb Lepore Boston syndrome. Uncommon differential diagnosis to homozygous sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2307460" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hb D Los Angeles (D-Punjab) and Hb Presbyterian: analysis of the defect at the DNA level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895770" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Facilitation of Hb S polymerization by the substitution of Glu for Gln at beta 121.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14363320" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical manifestations of inherited abnormal hemoglobins. I. The interaction of hemoglobin-S with hemoglobin-D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Double heterozygosity for hemoglobin S and D Punjab in Basra, Iraq: A Clinical and hematological study of 42 patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Sickle-cell anemia in a white American family</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6547933" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Life-threatening complications in a child with hemoglobin SD-Los Angeles disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11264186" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20788973" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Haemoglobin O in An Arab Family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37554704" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Molecular Detection of Hemoglobin O-Arab in the Sudanese Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5481775" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Hemoglobin O arab in four negro families and its interaction with hemoglobin S and hemoglobin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203101" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Hemoglobin S/O(Arab): thirteen new cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13205193" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Hemoglobin E, a hereditary abnormality of human hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7177196" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Abnormal RNA processing due to the exon mutation of beta E-globin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9668555" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The hemoglobin E syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278112" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hemoglobin SE disease: a concise review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/893130" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Hb-E in combination with Hb-S and Hb-C in a black family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10095824" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101436" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Sudden death after exercise in an adolescent with hemoglobin SE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37304489" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Clinico-Hematological Profile in Hemoglobin SE Disease: A Case Series from a Tertiary Care Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5673358" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : In vivo and in vitro interactions of human haemoglobins A,S and C with a variant haemoglobin E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25503918" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Incidence of sickle cell trait--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25503918" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Incidence of sickle cell trait--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34113458" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Non-S Sickling Hemoglobin Variants: Historical, Genetic, Diagnostic, and Clinical Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834244" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : HbS-oman heterozygote: a new dominant sickle syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470216" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Hemoglobin Jamaica plain--a sickling hemoglobin with reduced oxygen affinity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19055867" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Sickle cell disease in a carrier with pyruvate kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3467311" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
